Low-quality evidence suggests type/dose of steroid not linked to adverse psychological reactions, possibly associated with sleep problems
MONDAY, April 26, 2021 (HealthDay News) — For children with acute lymphoblastic leukemia (ALL), the type/dose of steroid seems not to be related to adverse psychological reactions (APRs) but may be associated with sleep problems, according to a review published online April 6 in Psycho-Oncology.
Annelienke M. van Hulst, from the Princess Maxima Center in Utrecht, Netherlands, and colleagues conducted a systematic review in six databases to identify risk factors for steroid-induced APRs and sleep problems in children with ALL. Data were included from 24 articles.
The researchers found that the quality of evidence was low overall. The type/dose of steroid was not related to APRs based on current evidence but was possibly related to sleep problems. Younger and older patients appeared to be at risk for behavioral problems and sleep problems, respectively. No studies were found describing parental stress or medical history. The associations of genetic susceptibility need to be replicated.
“Overall, these conclusions should be interpreted with caution,” the authors wrote. “One important recommendation is to implement a standardized prospective registration of both steroidâ€induced APRs and sleep problems and risk factors in future studies in children with ALL, since identifying children at risk and determining effective care can improve healthâ€related quality of life during treatment.”
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
Childhood Cancer Survivors Often Have Mental Distress in Adulthood
Mortality, Comorbidity Risk Increased With Generalized Pustular Psoriasis
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria